StatusThe thesis was presented on the 7 November, 2008
Approved by NCAA on the 22 January, 2009
Abstract– 0.35 Mb / in romanian
0.94 Mb /
This thesis is aimed at examination of problematic aspects of cost accounting and calculation of pharmaceutical production value.
Within the thesis we have analyzed, deepened and completed the notions of costs, production cost and calculation, as well as have argued in favor of their classification criteria. We have examined the manner of cost accounting in pharmaceutical production, identified its drawbacks and developed methods of improving this sector of accounting such as: application of the standard method in the model of responsibility accounting management aimed at prompt reporting of deviations, grouping indirect production costs in constant and variable ones, use of forms of internal reports on production which will ensure managers of different levels with current and useful information, application of two methods of distributing costs of auxiliary sections, etc. Special attention has been paid to adjusting of management accounts that will contain data about responsibility accounting and prompt observation of deviations from the norm.
Within the thesis we have also argued the necessity of implementing a method of costs calculation based on (ABC) activity in combination with the standard method that corresponds to organizational specificity of a pharmaceutical company and is considered a very efficient method of fulfilling management accounting objectives. In this context, we have determined methodological stages and rules of permanent implementation of the ABC method in pharmaceutical industry.
For the first time in the thesis we have revealed problems directly concerning management accounting – making decisions based on information about costs and expenditures. Thus, we have examined problems regarding equipment replacement, formation of prices for pharmaceutical production, as well as resolution of problems referring to deciding on the range of manufactured products.
Results of the investigation are of methodological and applicative character and may be implemented within pharmaceutical production companies with a view to improving cost accounting and calculation of value.